Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 1 - 25 of 1273 in total

Conestat alfa

C1 Esterase Inhibitor (Recombinant) is a recombinant analogue of endogenous complement component-1 esterase inhibitor (rhC1INH), purified from the milk of transgenic rabbits. The primary function of endogenous C1INH is to regulate the activation of the complement and contact system pathways. It does this through inhibition of several target proteases within...
Approved
Investigational
Matched Synonyms: … C1 Inhibitor (Recombinant) ... C1 Esterase Inhibitor (Recombinant) ... Complement C1 esterase inhibitor …
Matched Description: … inhibitor (rhC1INH), purified from the milk of transgenic rabbits. ... C1 Esterase Inhibitor (Recombinant) is a recombinant analogue of endogenous complement component-1 esterase ... Intravenous replacement of C1 esterase inhibitor results in reversal of acute symptoms of HAE. …

Mitapivat

Mitapivat is a novel, first-in-class pyruvate kinase activator. It works to increase the activity of erythrocyte pyruvate kinase, a key enzyme involved in the survival of red blood cells. Defects in the pyruvate kinase enzyme in various red blood cells disorders lead to the lack of energy production for red...
Approved
Investigational

Testolactone

An antineoplastic agent that is a derivative of progesterone and used to treat advanced breast cancer.
Approved
Investigational
Matched Categories: … Aromatase Inhibitors …

Triclocarban

Triclocarban, with the chemical formula C13H9Cl3N2O is an antibacterial agent that is particularly effective against Gram-positive bacteria such as Staphylococcus aureus. It is a bacteriostatic compound that has been found in antibacterial soaps and other personal care products. In 2017, the US FDA prohibited the marketing of over-the-counter (OTC) consumer...
Approved

Denosumab

Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss. Chemically, it consists of 2 heavy...
Approved
Matched Description: … deprivation therapy for non-metastatic prostate cancer and women at high risk for fracture receiving adjuvant aromatase ... It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss ... inhibitor therapy for breast cancer in September 2011 and in men with osteoporosis at high risk for …
Matched Categories: … RANK Ligand Inhibitor …

Lesinurad

Lesinurad is an oral uric acid transporter 1 (URAT1) inhibitor indicated for the treatment of hyperuricemia associated with gout. It reduces serum uric acid concentration through the inhibition of URAT1, an enzyme responsible for reuptake of uric acid from the renal tubule, and OAT4, another uric acid transporter associated with...
Approved
Investigational
Matched Description: … Lesinurad is an oral uric acid transporter 1 (URAT1) inhibitor indicated for the treatment of hyperuricemia ... Marketed as the product Zurampic, it is indicated for use in combination with a xanthine oxidase inhibitor ... with gout in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor …
Matched Categories: … Urate Transporter 1 Inhibitor …

Cisatracurium

Cisatracurium is a non-depolarising neuromuscular blocking agent of the benzylisoquinolinium class, available in its salt form, cisatracurium besylate.[A243416,A253592] Cisatracurium has an intermediate duration of action and is one of the most commonly used neuromuscular blocking agents in intensive care.[A253592,A253597]. Cisatracurium acts on cholinergic receptors, blocking neuromuscular transmission. This action is...
Approved
Investigational

Levomilnacipran

Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), although it is a more potent inhibitor of norepinephrine reuptake than serotonin reuptake.[A261181, A38560] Levomilnacipran is the more active 1S,2R-enantiomer in the racemate milnacipran.[A261181, L47956] Once administered, interconversion between levomilnacipran and its stereoisomer does not occur in humans. First approved...
Approved
Investigational
Matched Description: … a more potent inhibitor of norepinephrine reuptake than serotonin reuptake. ... Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), although it is …

Ocriplasmin

Ocriplasmin is a recombinant truncated form of human plasmin with a molecular weight of 27.2 kDa produced by recombinant DNA technology in a Pichia pastoris expression system. Ocriplasmin is a protein made up of 249 amino acids and has two peptide chains. Agent for pharmacologic vitreolysis; thrombolytic agent. FDA approved...
Approved

Viloxazine

Viloxazine is a selective norepinephrine reuptake inhibitor. For decades, an immediate-release formulation of viloxazine has been used in Europe as an antidepressant. It was first approved in the UK in 1974; however, the immediate-release formulation was discontinued due to business reasons unrelated to drug safety and efficacy. In the US,...
Approved
Investigational
Withdrawn
Matched Description: … Viloxazine is a selective norepinephrine reuptake inhibitor. …
Matched Categories: … Norepinephrine Reuptake Inhibitor …

Osilodrostat

Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiologically elevated. Cushing's...
Approved
Investigational
Matched Description: … Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes …

Acetohydroxamic acid

Acetohydroxamic Acid, a synthetic drug derived from hydroxylamine and ethyl acetate, is similar in structure to urea. In the urine, it acts as an antagonist of the bacterial enzyme urease. Acetohydroxamic Acid has no direct antimicrobial action and does not acidify urine directly. It is used, in addition to antibiotics...
Approved
Matched Categories: … Urease Inhibitor …

Simeprevir

Simeprevir is a hepatitis C virus (HCV) NS3/4A protease inhibitor indicated in patient's with HCV genotype 1 for the treatment of chronic hepatitis C virus (HCV) infection. HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United...
Approved
Matched Description: … [DB05521] but is classified as a second generation protease inhibitor. ... Simeprevir is a hepatitis C virus (HCV) NS3/4A protease inhibitor indicated in patient's with HCV genotype ... Like all NS3/4A inhibitors, simeprevir is a serine protease inhibitor in similarity to [DB08873] and …

Maralixibat

Maralixibat (also known as SHP625, LUM001, and lopixibat) is an ileal bile acid transporter inhibitor, like odevixibat.[A236823,A239249,L38834] Maralixibat is indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome. Previously, patients with cholestatic pruritus associated with Alagille syndrome were treated with antihistamines, rifampin, ursodeoxycholic acid, cholestyramine, naltrexone, and...
Approved
Investigational
Matched Description: … Maralixibat (also known as SHP625, LUM001, and lopixibat) is an ileal bile acid transporter inhibitor …
Matched Categories: … Ileal bile acid transport inhibitor ... Ileal Bile Acid Transporter Inhibitor …

Famciclovir

Famciclovir, marketed as Famvir by Novartis, is a guanine analogue used to treat herpes virus infections. It is most commonly used to treat herpes zoster (shingles). Famciclovir is a prodrug of penciclovir with higher oral bioavailability.
Approved
Investigational
Matched Categories: … Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor ... Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor …

Cobimetinib

Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or...
Approved
Investigational
Matched Categories: … Kinase Inhibitor …

Sunitinib

Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation....
Approved
Investigational
Matched Description: … Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. …
Matched Categories: … Kinase Inhibitor …

Damoctocog alfa pegol

In recent years, various extended half-life factor VIII and factor IX preparations have been studied and gained approval. In order to extend half-lives, techniques such as fusion to protein conjugates (Fc part of IgG1 or albumin), chemical modification (PEGylation), and protein sequence modification have been utilized. Also known as, BAY94-9027,...
Approved
Investigational

Thrombin

Also known as coagulation factor II, thrombin is a serine protease that plays a physiological role in regulating hemostasis and maintaining blood coagulation. Once converted from prothrombin, thrombin converts fibrinogen to fibrin, which, in combination with platelets from the blood, forms a clot. Medical thrombin is a protein substance produced...
Approved
Investigational

Nilotinib

Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant...
Approved
Investigational
Matched Description: … Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment ... CML which were found to be resistant to treatment with imatinib (Gleevec), another tyrosine kinase inhibitor …
Matched Categories: … Kinase Inhibitor …

Tolcapone

Tolcapone is a drug that inhibits the enzyme catechol-O-methyl transferase (COMT). It is used in the treatment of Parkinson's disease as an adjunct to levodopa/carbidopa medication. It is a yellow, odorless, non-hygroscopic, crystalline compound. Tolcapone is associated with a risk of hepatotoxicity.
Approved
Withdrawn

Copanlisib

Copanlisib is a selective pan-Class I phosphoinositide 3-kinase (PI3K) inhibitor with preferential activity against the alpha and delta isoforms. PI3K, a lipid kinase that activates downstream signalling pathways involved in cell survival and growth, that exists in different isoforms and is often overexpressed in hematological malignancies. Copanlisib was granted accelerated...
Approved
Investigational
Matched Description: … Copanlisib is a selective pan-Class I phosphoinositide 3-kinase (PI3K) inhibitor with preferential activity …
Matched Categories: … Kinase Inhibitor …

Sutimlimab

Cold agglutinin disease (CAD) is a type of autoimmune hemolytic anemia (AIHA) in which autoantibodies directed against red blood cell surface antigens cause hemolysis at low (3-4°C) temperatures.[A245154,L40114] This cold subtype accounts for approximately 15-25% of all AIHA and is more common in the elderly.[A245159,L40114] In approximately 90% of cases,...
Approved
Investigational
Matched Description: … of the complement system with drugs like [eculizumab], an anti-C5 mAb, and [pegcetacoplan], a novel inhibitor …
Matched Categories: … Classical Complement Pathway Inhibitor …

Loxoprofen

Loxoprofen is a propionic acid derivative non-steroidal anti-inflammatory drug. It is marketed under the trade name Loxonin in Brazil, Mexico and Japan by Sankyo, as Loxomac in India, and as Oxeno in Argentina. A transdermal preparation was approved for use in Japan in January 2006.
Approved

Saxagliptin

Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009.
Approved
Matched Description: … rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor …
Displaying drugs 1 - 25 of 1273 in total